Neural biofeedback: Biofeedback using real-time EEG or fMRI to illustrate brain activity, often with a goal of controlling the central nervous actions.
Scientifically viable today; mainstream in 2015; financially viable in 2017.
Capacitive micromachined ultrasonic transducers: A relatively new concept in the field of ultrasonic transducers where the energy transduction is due to change in capacitance. Can be used to remotely improve alertness, awareness in soldiers, etc.
Scientifically viable in 2016; mainstream in 2019; financially viable in 2020.
Next-generation neuropharmacology: Both behavioural and molecular neuropharmacology are benefitting from rapidly accelerating change. With an increase in technology and improved understanding of the nervous system, the development of drugs will continue to rise with an increase in drug sensitivity and specificity. (Such as neuropharmacological enhancements that work better than caffeine).
Scientifically viable in 2018; mainstream in 2021; financially viable in 2023.
Neuroprosthetics: Neural devices capable of substituting motor, sensory or cognitive modalities that might have been damaged as a result of an injury or a disease. Applications include neural enhancements, advanced cognitive features and extended physiological senses.
Scientifically viable in 2021; mainstream in 2026; financially viable in 2027.
Address: 5636 Lemon Ave.
Dallas TX 75209
Phone: +1 214 5203694